BioLife Solutions, Inc.
BLFS
Health Care
2
exclusion reasons
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
BioLife Solutions develops and markets biopreservation media products and equipment essential for the collection, processing, and cryopreservation of biological materials, including animal cells and tissues. This technology is foundational for industries reliant on animal testing and exploitation, such as pharmaceutical development and biomedical research, where animal-derived cells are a standard input. The company’s product portfolio directly supports the infrastructure that enables animal testing at scale.
Cruelty Free Investors flags BioLife Solutions for its role in this supply chain. The company’s equipment and media are used to preserve biological specimens, which often originate from animals subjected to testing procedures. By providing critical tools for these industries, BioLife Solutions facilitates the commercial systems of animal exploitation, even if its products are not the final tested items themselves.
BioLife Solutions, Inc. develops and supplies bioproduction tools and services for the cell and gene therapy industry. A core component of its business involves providing biopreservation media and other products used in the development and manufacturing of biologic therapies, a process that inherently requires pre-clinical animal testing for regulatory approval. According to Cruelty Free Investors, the company is listed for exploiting animals in drug testing during pre-clinical trials, indicating its products and services are integral to research activities that commission or require animal testing.
The company’s product portfolio, including its hypothermic storage and cryopreservation media, is marketed for use in veterinary regenerative medicine and human cell therapy applications, both of which rely on animal models in the development pathway. BioLife’s business model is built on supporting the biopharmaceutical and advanced therapy sectors, where animal testing remains a standard regulatory requirement for safety and efficacy studies. The company’s financial dependence on these research and development workflows places it within the animal testing supply chain.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.